{"meta":{"query_hash":"b2d2ae028a2a","filters":{"venue":"Vivli"},"cohort_total":21,"direct_labels_cover":0,"predictions_cover":21,"exported":21,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b2d2ae028a2a","api":"https://metacan.xera.ac/api/v1/cohort?venue=Vivli"},"results":[{"id":"W6889596690","doi":"10.25934/pr00009377","title":"Biomarker discovery for immunotherapy response via pan-cancer and cancer-specific analyses","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Biomarker discovery; Immunotherapy; Informatics; Immune checkpoint; Cancer; Clinical trial; Biomarker; Cancer immunotherapy; Cancer biomarkers","score_opus":0.06698971287844391,"score_gpt":0.40139031952049836,"score_spread":0.33440060664205445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6889596690","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46270233,0.14828157,0.3163181,0.009290704,0.0014677607,0.0012972591,0.049434304,0.0027684313,0.008439616],"genre_scores_gemma":[0.9191117,0.006861488,0.056884058,0.0017366584,0.00064142945,0.00069785654,0.012698953,0.00025384407,0.0011139705],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99106795,0.0045570666,0.0010255662,0.002238532,0.0007799724,0.00033089225],"domain_scores_gemma":[0.98178357,0.01066809,0.0034696101,0.0022392066,0.0014554852,0.00038410304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02062238,0.0015093847,0.0034646022,0.007920421,0.0005843103,0.0033010242,0.0011044545,0.0011254343,0.0030963318],"category_scores_gemma":[0.030322155,0.00048835215,0.0062052836,0.010889531,0.0006134365,0.0019144481,0.0017410077,0.0015863684,0.0005441082],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034921956,0.00028721904,0.7106189,0.0049188565,0.053870797,0.0005126145,0.0002964596,0.0208112,0.0083199395,0.00446855,0.008999355,0.18340388],"study_design_scores_gemma":[0.00083308085,0.00309792,0.5406838,0.0016121765,0.10282378,0.0024117916,0.0008903921,0.14821078,0.01704478,0.09497688,0.086946726,0.00046797204],"about_ca_topic_score_codex":0.0017361994,"about_ca_topic_score_gemma":0.0023675787,"teacher_disagreement_score":0.02062238,"about_ca_system_score_codex":0.00085624977,"about_ca_system_score_gemma":0.0014479257,"threshold_uncertainty_score":0.10906291},"labels":[],"label_agreement":null},{"id":"W6889640636","doi":"10.25934/00005663","title":"A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis","year":2020,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multicenter study; Rituximab; Placebo; Multiple sclerosis; Phases of clinical research; Multicenter trial","score_opus":0.03169117088397654,"score_gpt":0.30439366155607633,"score_spread":0.2727024906720998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6889640636","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028993776,0.0035876196,0.0023381785,0.0024004504,0.00043777068,0.014693522,0.9379404,0.00059577305,0.009012521],"genre_scores_gemma":[0.0660674,0.0035240876,0.011630332,0.0039212056,0.00028051334,0.044096816,0.8593772,0.0002127214,0.01088959],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841297,0.000904535,0.00012531622,0.00018388996,0.00025064405,0.00012259645],"domain_scores_gemma":[0.99679404,0.0007814682,0.00088670594,0.00040363375,0.00060346193,0.00053071586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054612504,0.0017215392,0.002686158,0.0005943094,0.0007161795,0.0011145142,0.0025481163,0.0016129229,0.0228421],"category_scores_gemma":[0.0074923118,0.0006312029,0.0014966605,0.0011030576,0.00039093578,0.0006982699,0.0007442669,0.0016432499,0.004743567],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39175388,0.0043754247,0.011841635,0.007691632,0.0054311873,0.00016620128,0.00009244551,0.0012112816,0.0019224808,0.0014024712,0.5239861,0.050125256],"study_design_scores_gemma":[0.8139483,0.008181355,0.03540115,0.0011218631,0.0041071535,0.00028871527,0.00006302438,0.0018062897,0.00085544656,0.0015232374,0.13259606,0.000107322056],"about_ca_topic_score_codex":0.011293141,"about_ca_topic_score_gemma":0.029011166,"teacher_disagreement_score":0.0228421,"about_ca_system_score_codex":0.0017183111,"about_ca_system_score_gemma":0.0047493814,"threshold_uncertainty_score":0.076414466},"labels":[],"label_agreement":null},{"id":"W6889692353","doi":"10.25934/pr00009332","title":"Outcomes from Induction Using Ustekinumab or Vedolizumab Among Patients Who Have Prior Biologic Intolerance vs Biologic Failure in Ulcerative colitis and Crohn's disease","year":2024,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Ulcerative colitis; Ustekinumab; Vedolizumab; Inflammatory bowel disease; Disease; Abdominal pain; Crohn's disease","score_opus":0.03290112867001576,"score_gpt":0.2922660289213194,"score_spread":0.25936490025130365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6889692353","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847974,0.012113398,0.00008621651,0.0005137311,0.00013176585,0.00005639929,0.00063129916,0.000006699456,0.001663067],"genre_scores_gemma":[0.9957646,0.0020342323,0.00006569523,0.0004208137,0.00015515125,0.00005597357,0.0011575364,0.0000027945684,0.0003431983],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993262,0.0001768388,0.000092386064,0.000107287204,0.00010757131,0.00018963749],"domain_scores_gemma":[0.9975114,0.00044487932,0.0011140194,0.00006569603,0.00011755864,0.0007464184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009753364,0.00022183478,0.0009932393,0.000405906,0.00041251883,0.0008892438,0.00035497604,0.0006626021,0.0021663248],"category_scores_gemma":[0.002423308,0.00014493796,0.0023510521,0.00069906126,0.0003082737,0.00071247795,0.0007012101,0.0017689621,0.00025203984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068760805,0.0017178915,0.8412447,0.0012471235,0.0022801687,0.00051120913,0.00038204307,0.0008042679,0.0011820298,0.00043484755,0.0034541895,0.07798067],"study_design_scores_gemma":[0.0036724347,0.014875652,0.97211343,0.000692313,0.002416328,0.000769127,0.0005274258,0.0009828048,0.00032761862,0.0004756723,0.003092714,0.000054452037],"about_ca_topic_score_codex":0.0011737947,"about_ca_topic_score_gemma":0.0018369606,"teacher_disagreement_score":0.0021663248,"about_ca_system_score_codex":0.0006527913,"about_ca_system_score_gemma":0.0005005858,"threshold_uncertainty_score":0.0072470903},"labels":[],"label_agreement":null},{"id":"W6889769029","doi":"10.25934/pr00007817","title":"Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis","year":2023,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Eosinophilic esophagitis; Mepolizumab; Immune system; Eosinophilia; Histology; Eosinophilic gastroenteritis; Eosinophil; Immunopathology; Eosinophilic","score_opus":0.040766438307184606,"score_gpt":0.3077268666848046,"score_spread":0.26696042837761996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6889769029","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99569255,0.00309874,0.0001284463,0.00010868978,0.00001493458,0.000029702715,0.0003913687,0.00000514399,0.000530407],"genre_scores_gemma":[0.99849725,0.00057078537,0.00021102895,0.000043513326,0.00002894353,0.00001736533,0.0004853619,0.0000014512937,0.00014429829],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996697,0.000085734726,0.000053949832,0.000050152477,0.000084988555,0.000055509074],"domain_scores_gemma":[0.9984295,0.00040439915,0.0007253514,0.000038010257,0.00014420116,0.00025851314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006402993,0.0002234168,0.00042556238,0.00038089865,0.00016353377,0.00038185937,0.00024299852,0.00039423292,0.0014220658],"category_scores_gemma":[0.0016658955,0.00010361503,0.0003668883,0.00047893415,0.00013423608,0.0003800443,0.00023467065,0.000767815,0.00019714817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007862792,0.00009428532,0.9956731,0.000027038532,0.000060789494,0.00004867864,0.000016347545,0.00005859743,0.0003402622,0.0000061364767,0.00008209716,0.0028063029],"study_design_scores_gemma":[0.000036207657,0.000863032,0.99785966,0.000022107242,0.00008781799,0.00029001158,0.00004526389,0.00031575232,0.00017739367,0.0000116460105,0.00028788345,0.0000031752213],"about_ca_topic_score_codex":0.0005720971,"about_ca_topic_score_gemma":0.0012667901,"teacher_disagreement_score":0.0014220658,"about_ca_system_score_codex":0.00016573747,"about_ca_system_score_gemma":0.00019921904,"threshold_uncertainty_score":0.0047573447},"labels":[],"label_agreement":null},{"id":"W6908286552","doi":"10.25934/pr00010843","title":"Efficacy of Glucose-Lowering Drugs for Young-Onset Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomized Control Trials","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Type 2 diabetes; Diabetes mellitus; Blood sugar; Drug; Randomized controlled trial; Clinical trial; MEDLINE","score_opus":0.23755518306215315,"score_gpt":0.4037007682444479,"score_spread":0.16614558518229475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908286552","genre_codex":"review","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06557097,0.9172874,0.006962277,0.0010839681,0.0014193442,0.00096607435,0.005158277,0.0002675122,0.0012841383],"genre_scores_gemma":[0.8131854,0.1647667,0.009177665,0.0024347145,0.00066858745,0.0027857851,0.005843373,0.00022306482,0.00091469294],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9682841,0.021244038,0.0053102584,0.0026644804,0.0018183092,0.00067883753],"domain_scores_gemma":[0.95246255,0.037239853,0.005063437,0.0028132473,0.0018343853,0.00058652513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03556096,0.0029469978,0.016440379,0.0038941954,0.0005249875,0.0032049837,0.0022602817,0.0023172495,0.003376139],"category_scores_gemma":[0.056507226,0.0016092614,0.05992337,0.004992509,0.0006215489,0.002048697,0.0015759794,0.0035369685,0.0003375333],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008066012,0.000027673417,0.005617933,0.02321276,0.958187,0.00006293754,0.000030282376,0.00065691496,0.00011235956,0.00009027966,0.0005083774,0.003427453],"study_design_scores_gemma":[0.0028722896,0.00025205413,0.0053542177,0.001590663,0.98819715,0.000048092115,0.000023329667,0.0004685022,0.000094051116,0.00030167334,0.00077373633,0.000024215746],"about_ca_topic_score_codex":0.0054724035,"about_ca_topic_score_gemma":0.0075699505,"teacher_disagreement_score":0.03556096,"about_ca_system_score_codex":0.001564391,"about_ca_system_score_gemma":0.0016071597,"threshold_uncertainty_score":0.1880666},"labels":[],"label_agreement":null},{"id":"W6908434345","doi":"10.25934/pr00006175.0","title":"Available IPD datapackage for study 'A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States'","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Metformin; Dapagliflozin; Fixed-dose combination; Glimepiride; Pharmacokinetics","score_opus":0.028447656499054834,"score_gpt":0.32291868140233104,"score_spread":0.2944710249032762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908434345","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001282253,0.00012063541,0.00007218468,0.000054800534,0.000017535223,0.000022682336,0.9991315,0.00014458907,0.00030787181],"genre_scores_gemma":[0.0006117472,0.000086012304,0.0003170059,0.000081613245,0.00000901779,0.00017037163,0.9982192,0.000046473495,0.00045849962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819416,0.00046164493,0.00028751232,0.00045367455,0.00042466575,0.00017839199],"domain_scores_gemma":[0.9949368,0.002164539,0.0008109559,0.0009330655,0.00086733914,0.0002873097],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029170215,0.0024843414,0.002138254,0.0022468367,0.000602798,0.0019182932,0.003252646,0.0035474978,0.078348376],"category_scores_gemma":[0.013286022,0.00078681484,0.0023830656,0.00414658,0.000518771,0.0010340741,0.0015997986,0.0018292388,0.06304619],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005345712,0.00008362721,0.0017885026,0.0030957537,0.00025376765,0.000038792692,0.000022375032,0.0010083015,0.00020957118,0.0005372728,0.9882917,0.004135755],"study_design_scores_gemma":[0.0041205822,0.00018173589,0.00886397,0.001178153,0.00041641752,0.00012624061,0.00004833226,0.0018588689,0.00062089716,0.002300447,0.9802085,0.00007573422],"about_ca_topic_score_codex":0.02189339,"about_ca_topic_score_gemma":0.034367893,"teacher_disagreement_score":0.9781066,"about_ca_system_score_codex":0.0015080601,"about_ca_system_score_gemma":0.0032980682,"threshold_uncertainty_score":0.2621014},"labels":[],"label_agreement":null},{"id":"W6908450664","doi":"10.25934/pr00004920","title":"Predicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Douglas Mental Health University Institute","funders":"","keywords":"Depression (economics); Mental illness; Neurostimulation; Mental health; Clinical trial","score_opus":0.023266697065248945,"score_gpt":0.283555226787726,"score_spread":0.26028852972247707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908450664","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9056275,0.010246177,0.05300119,0.008124946,0.0005035739,0.00040866662,0.014433409,0.00066334405,0.0069913645],"genre_scores_gemma":[0.9865124,0.0010318027,0.007324763,0.0006388811,0.00016927987,0.00016306926,0.0032680607,0.000023041135,0.00086871383],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961483,0.0001252003,0.000049673927,0.00009152025,0.000060531245,0.00005818153],"domain_scores_gemma":[0.99889094,0.00069856254,0.00016813712,0.000045692006,0.00011294654,0.000083691906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011951359,0.00060042104,0.00080041913,0.0007747839,0.00018844297,0.0009198823,0.0004534575,0.00092554576,0.0020638707],"category_scores_gemma":[0.0059467945,0.00021548397,0.00071545946,0.00044597726,0.00016650617,0.0005507242,0.00045257033,0.0013329262,0.000521308],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035523358,0.0019449401,0.48726195,0.0006719434,0.0013746709,0.00045701631,0.00021086853,0.092259586,0.003043617,0.0014724709,0.0258513,0.38189936],"study_design_scores_gemma":[0.00024985144,0.0010273057,0.15828644,0.00039238267,0.000521049,0.00035978467,0.00023701592,0.82640946,0.0017773838,0.0075198906,0.0031557265,0.000063721316],"about_ca_topic_score_codex":0.0046303114,"about_ca_topic_score_gemma":0.007084769,"teacher_disagreement_score":0.0046303114,"about_ca_system_score_codex":0.0006676109,"about_ca_system_score_gemma":0.00046600375,"threshold_uncertainty_score":0.009206712},"labels":[],"label_agreement":null},{"id":"W6908464859","doi":"10.25934/00005706","title":"A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters","year":2020,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tenecteplase; Dysfunctional family; Phase (matter); Function (biology); Central venous catheter","score_opus":0.08591047963763426,"score_gpt":0.32876284178824305,"score_spread":0.2428523621506088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908464859","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48769933,0.017878108,0.005994771,0.004488714,0.0010205355,0.02481807,0.43492797,0.0011560884,0.022016458],"genre_scores_gemma":[0.547147,0.014199031,0.0149445115,0.007834118,0.000527643,0.047840502,0.34932485,0.00033852246,0.017843824],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9994153,0.00030290504,0.000025966536,0.00008293647,0.00008573646,0.00008709848],"domain_scores_gemma":[0.9988959,0.0002462983,0.0002520122,0.000121836885,0.0001738593,0.00031010064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027436074,0.0014279282,0.002033105,0.00035666703,0.0004307613,0.0010243171,0.0015133215,0.0011906147,0.0075154025],"category_scores_gemma":[0.0023028583,0.0004605844,0.0012529984,0.0006226045,0.0004496278,0.0005200779,0.0004059867,0.0020534191,0.001856405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5742021,0.028401848,0.011701316,0.0053828075,0.004932674,0.00033213678,0.00015633248,0.005567358,0.010216221,0.0014378569,0.24594295,0.111726426],"study_design_scores_gemma":[0.8685099,0.042426992,0.020676298,0.0005235322,0.0025576572,0.00044852655,0.00007714069,0.004320199,0.0017157579,0.000994243,0.057648342,0.00010141191],"about_ca_topic_score_codex":0.0059915255,"about_ca_topic_score_gemma":0.017792802,"teacher_disagreement_score":0.0075154025,"about_ca_system_score_codex":0.0015817289,"about_ca_system_score_gemma":0.0049219592,"threshold_uncertainty_score":0.025141537},"labels":[],"label_agreement":null},{"id":"W6927326088","doi":"10.25934/00006041","title":"Histologic Predictors of Endoscopic Healing in Crohn's Disease","year":2023,"lang":"en","type":"dataset","venue":"Vivli","topic":"Bacillus and Francisella bacterial research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Disease; Endoscopy; Abdominal pain; Clinical trial; Inflammatory bowel disease; Ustekinumab; Crohn's disease; Gastrointestinal tract","score_opus":0.019005653703053564,"score_gpt":0.2862654836652848,"score_spread":0.26725982996223124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6927326088","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93730545,0.056514386,0.00082746055,0.000632387,0.0001779239,0.00004837541,0.000778867,0.000025559213,0.0036895957],"genre_scores_gemma":[0.9923494,0.0054588914,0.00066704076,0.00009998585,0.00019861174,0.000015207634,0.0007672768,0.000007490498,0.00043601426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994886,0.00017691056,0.00007132552,0.000060701754,0.00014386183,0.00005863486],"domain_scores_gemma":[0.9956571,0.00121411,0.0020033033,0.00014350878,0.0004433104,0.00053873076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017992416,0.00034679653,0.0005234341,0.00089481217,0.00021588705,0.0006343346,0.00036191233,0.00049382827,0.0023137466],"category_scores_gemma":[0.005449536,0.00014386493,0.00038934246,0.0013423836,0.00034008906,0.0005034529,0.00046122537,0.0011750545,0.00032929803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006061117,0.000057408957,0.9886496,0.00012783341,0.00009548966,0.0000939388,0.000024851548,0.00008174265,0.0002547914,0.000040142175,0.00025857435,0.009709425],"study_design_scores_gemma":[0.000027937389,0.00034494963,0.99678516,0.00009444897,0.0001454863,0.0005743814,0.0001214522,0.00042542268,0.00015729107,0.00010987181,0.0012068779,0.0000067505525],"about_ca_topic_score_codex":0.0008940333,"about_ca_topic_score_gemma":0.0015086117,"teacher_disagreement_score":0.0023137466,"about_ca_system_score_codex":0.00020839034,"about_ca_system_score_gemma":0.0002252232,"threshold_uncertainty_score":0.009515405},"labels":[],"label_agreement":null},{"id":"W6945877751","doi":"10.25934/00005318","title":"Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions","year":2020,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Paroxetine; Bioequivalence; Crossover study; Open label; Anxiety; Randomized controlled trial","score_opus":0.12495461603626387,"score_gpt":0.39631894624468256,"score_spread":0.27136433020841866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6945877751","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057553194,0.0013050825,0.0024509989,0.0010477769,0.0002155044,0.010051443,0.92176914,0.0007050137,0.004901876],"genre_scores_gemma":[0.100978486,0.0008310542,0.0089927865,0.0016152296,0.00009762722,0.032739133,0.8455866,0.000136158,0.009022918],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99745935,0.0013159513,0.00027387717,0.0004539261,0.000350654,0.00014627691],"domain_scores_gemma":[0.9960886,0.0010212949,0.00095525454,0.00090843125,0.0007035684,0.00032281515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071618524,0.0014813732,0.0028531202,0.00051971467,0.0005662218,0.0009467157,0.0029983902,0.0019232616,0.025893543],"category_scores_gemma":[0.009041937,0.0005386026,0.0016739714,0.00114468,0.00063005515,0.0006067531,0.0009423546,0.0013821536,0.00677539],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3037138,0.009278893,0.023531115,0.011139386,0.00546595,0.00035583644,0.00023288168,0.0035293782,0.003274068,0.002461963,0.58061683,0.056399833],"study_design_scores_gemma":[0.42187068,0.021398043,0.15158656,0.0021565761,0.009745909,0.0007567093,0.00025686706,0.01482388,0.0037326012,0.0032827456,0.36987114,0.00051832484],"about_ca_topic_score_codex":0.008630973,"about_ca_topic_score_gemma":0.01476097,"teacher_disagreement_score":0.025893543,"about_ca_system_score_codex":0.0017541752,"about_ca_system_score_gemma":0.003442999,"threshold_uncertainty_score":0.086622536},"labels":[],"label_agreement":null},{"id":"W6945990900","doi":"10.25934/00003792","title":"Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis","year":2019,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atopic dermatitis; Randomized controlled trial; Multicenter study; Atopy; Clinical trial; Clinical study","score_opus":0.06535152408763242,"score_gpt":0.344640428952276,"score_spread":0.27928890486464353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6945990900","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9248779,0.0040399022,0.0025450515,0.0013443031,0.00088336697,0.05146921,0.0048740422,0.0005190868,0.009447194],"genre_scores_gemma":[0.89138985,0.005430809,0.010617027,0.0062379446,0.0016040967,0.06622147,0.0052500786,0.00012408385,0.013124498],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980129,0.001241311,0.00016564218,0.0001639491,0.00023913743,0.00017711832],"domain_scores_gemma":[0.9983418,0.0004978349,0.00030426783,0.00014292335,0.00018997518,0.0005231355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032763504,0.001810666,0.003815431,0.00066743983,0.0008794059,0.00081311277,0.0012281699,0.003241517,0.008557517],"category_scores_gemma":[0.0023623325,0.000857024,0.0013420058,0.0004631158,0.00084519025,0.00095945486,0.00042893057,0.0032091376,0.002606452],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.81823826,0.09887915,0.0013425146,0.002034017,0.00057218486,0.0002233708,0.00012893259,0.00040798093,0.028855147,0.00039649132,0.005721505,0.043200552],"study_design_scores_gemma":[0.6254557,0.36894846,0.0017505822,0.000038849084,0.00014670289,0.00009018146,0.000019774847,0.00027115163,0.0016147057,0.0000701358,0.0015671405,0.000026697402],"about_ca_topic_score_codex":0.0008871513,"about_ca_topic_score_gemma":0.002609451,"teacher_disagreement_score":0.008557517,"about_ca_system_score_codex":0.00068426295,"about_ca_system_score_gemma":0.0033477447,"threshold_uncertainty_score":0.028627813},"labels":[],"label_agreement":null},{"id":"W6946015985","doi":"10.25934/pr00008602","title":"Statin use and prostate cancer outcomes in patients treated in the ARAMIS trial","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Prostate cancer; Statin; Concomitant; Disease; Cancer; Testosterone (patch); Prostate","score_opus":0.026714472832916922,"score_gpt":0.320700576742342,"score_spread":0.29398610390942503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6946015985","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9207219,0.060192578,0.00020357655,0.003775731,0.00063014304,0.00024420896,0.003924142,0.000053155574,0.010254647],"genre_scores_gemma":[0.9883718,0.0063762693,0.00013155151,0.0011438024,0.00027269783,0.00011436742,0.0022919634,0.000006297964,0.0012913208],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99936455,0.00026364642,0.00008804166,0.00008747538,0.00009174583,0.00010451358],"domain_scores_gemma":[0.9992975,0.000110925655,0.00025434687,0.000052690662,0.00007577599,0.00020873515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008769889,0.00020437298,0.000819353,0.00024158451,0.00029438568,0.00087916176,0.0002781471,0.00090810505,0.002143941],"category_scores_gemma":[0.0023886496,0.00018764383,0.0014552273,0.000578961,0.00018697589,0.0005471337,0.00034476526,0.0015610794,0.00031178363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42457515,0.0042480472,0.36417854,0.0065762796,0.017889565,0.00034135726,0.00034081077,0.0018582164,0.0030975458,0.001970605,0.023645895,0.15127808],"study_design_scores_gemma":[0.082835935,0.027846951,0.8418569,0.0022145181,0.018057413,0.00054324296,0.00039924498,0.0029773535,0.0010418803,0.0030542943,0.018972341,0.00020003089],"about_ca_topic_score_codex":0.0024281,"about_ca_topic_score_gemma":0.0053711263,"teacher_disagreement_score":0.0024281,"about_ca_system_score_codex":0.0004352823,"about_ca_system_score_gemma":0.0006394193,"threshold_uncertainty_score":0.007172227},"labels":[],"label_agreement":null},{"id":"W6946233082","doi":"10.25934/pr00010916","title":"Predictability of biomarkers and disease activity indices for efficacy of advanced therapies in Crohn’s disease","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Disease; Ulcerative colitis; Inflammatory bowel disease; Abdominal pain; Clinical disease; Inflammation; Biomarker; Predictability","score_opus":0.011829668045950674,"score_gpt":0.3044365102672706,"score_spread":0.29260684222131994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6946233082","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9207692,0.055385243,0.009155359,0.0017693355,0.00072482723,0.00026074908,0.006257794,0.00022197636,0.0054555014],"genre_scores_gemma":[0.99110234,0.0025505768,0.002885642,0.00020702765,0.00029055146,0.000085425476,0.0025216155,0.000017053026,0.000339708],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974251,0.0010175655,0.0004725476,0.00042432902,0.00048080462,0.00017972474],"domain_scores_gemma":[0.98378754,0.009214778,0.0043845773,0.000712781,0.001185743,0.00071442616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004702662,0.0010189372,0.0021161302,0.001824612,0.00027817863,0.0017601866,0.00040480436,0.00095961714,0.0018847927],"category_scores_gemma":[0.01891793,0.00033406576,0.0018336165,0.0021927664,0.00037393247,0.0011262376,0.0006986953,0.0021994065,0.00074886496],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023085778,0.00020963146,0.9577085,0.0003987003,0.0011160902,0.000110158406,0.00009113094,0.003677854,0.00055358565,0.00031340026,0.0017550536,0.03175729],"study_design_scores_gemma":[0.0002003355,0.0019589611,0.95348006,0.00043649308,0.0016268013,0.00047930243,0.00021845903,0.03176657,0.0011989858,0.002593914,0.0059455433,0.00009466013],"about_ca_topic_score_codex":0.00091284595,"about_ca_topic_score_gemma":0.0009759932,"teacher_disagreement_score":0.004702662,"about_ca_system_score_codex":0.00041555002,"about_ca_system_score_gemma":0.000461851,"threshold_uncertainty_score":0.024870336},"labels":[],"label_agreement":null},{"id":"W6964497678","doi":"10.25934/pr00010997","title":"Re-analyzing Heart Failure Treatment Outcomes Based on Patient Preferences: A Study Using Data from Multiple Clinical Trials","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Clinical trial; Quality of life (healthcare); Heart failure; Quality (philosophy); Event (particle physics); Balance (ability)","score_opus":0.5015705775995087,"score_gpt":0.5093918840397282,"score_spread":0.0078213064402195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6964497678","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6261292,0.18337555,0.11845782,0.009066148,0.00545561,0.017370103,0.0296813,0.00073351804,0.009730741],"genre_scores_gemma":[0.9000953,0.0068076616,0.058078084,0.005393838,0.0013495577,0.0154128065,0.01131331,0.00029484567,0.0012546271],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.56992847,0.32484892,0.055832513,0.022436552,0.024472957,0.0024807358],"domain_scores_gemma":[0.33950722,0.4844336,0.09575589,0.06134458,0.016027892,0.002930809],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.26921585,0.0038560468,0.0120941335,0.006251921,0.0016448802,0.0072003393,0.004376627,0.004395263,0.0067938757],"category_scores_gemma":[0.45651534,0.0014798056,0.03684867,0.0122157885,0.002305951,0.0093859285,0.0038539923,0.005587818,0.0011623318],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051178798,0.0017599079,0.26628017,0.025675355,0.55708265,0.0008337393,0.0012808671,0.0062339795,0.0012674219,0.002649037,0.005685058,0.08007301],"study_design_scores_gemma":[0.039523784,0.024153097,0.27533993,0.009078387,0.5501421,0.0031911472,0.0017627904,0.039085902,0.0029296575,0.016026812,0.037353463,0.0014128849],"about_ca_topic_score_codex":0.0013132215,"about_ca_topic_score_gemma":0.002037911,"teacher_disagreement_score":0.26921585,"about_ca_system_score_codex":0.00225897,"about_ca_system_score_gemma":0.0019825725,"threshold_uncertainty_score":0.90118694},"labels":[],"label_agreement":null},{"id":"W6964545150","doi":"10.25934/pr00009081","title":"Antidepressant effects of bupropion, varenicline, nicotine replacement therapy, and placebo in tobacco users.","year":2023,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Varenicline; Nicotine; Craving; Antidepressant; Placebo; Smoking cessation; Bupropion; Mood; Nicotine replacement therapy","score_opus":0.01985587081442298,"score_gpt":0.2815772220963098,"score_spread":0.26172135128188684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6964545150","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.955081,0.03764021,0.00025990425,0.000644828,0.0006285693,0.0008659592,0.0009168474,0.00009047474,0.0038721743],"genre_scores_gemma":[0.97718006,0.01582347,0.00094843353,0.0005790684,0.0004089125,0.0007762478,0.00077364943,0.000011330441,0.0034988453],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99930775,0.0003527839,0.00010381308,0.00007170515,0.000085971624,0.000077953686],"domain_scores_gemma":[0.99945897,0.00017518863,0.00013700906,0.000038458045,0.000051251696,0.00013908569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010712342,0.00045967693,0.0016438742,0.00048876385,0.0002384851,0.00040446722,0.00045107043,0.000848861,0.005125927],"category_scores_gemma":[0.0015445497,0.00042782593,0.0010947536,0.00036676714,0.00033974668,0.0006306004,0.0002899106,0.0012925023,0.00056829065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73916364,0.018452514,0.001868833,0.0025702827,0.002274698,0.00018804178,0.00027380275,0.0002899839,0.028328348,0.00031247048,0.0019811087,0.20429632],"study_design_scores_gemma":[0.34830388,0.5986893,0.034370333,0.00031882682,0.0027328802,0.0004971928,0.0002423844,0.0013587311,0.0068941345,0.0003352996,0.006192228,0.00006491054],"about_ca_topic_score_codex":0.0007341117,"about_ca_topic_score_gemma":0.0018946311,"teacher_disagreement_score":0.005125927,"about_ca_system_score_codex":0.00031321874,"about_ca_system_score_gemma":0.000351666,"threshold_uncertainty_score":0.017147958},"labels":[],"label_agreement":null},{"id":"W6964672847","doi":"10.25934/00000684","title":"An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga","year":2018,"lang":"en","type":"dataset","venue":"Vivli","topic":"Forest Ecology and Biodiversity Studies","field":"Agricultural and Biological Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Bioequivalence; Paroxetine; Immediate release; Crossover study; Controlled release; Dosage form","score_opus":0.04077867042252856,"score_gpt":0.2877597463769197,"score_spread":0.24698107595439114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6964672847","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061307058,0.0021644265,0.0018707147,0.0010938387,0.00026300192,0.009495455,0.91625845,0.00046660082,0.0070804236],"genre_scores_gemma":[0.13118114,0.001361003,0.008480738,0.0017550365,0.00018435746,0.03715403,0.8097296,0.00018009575,0.009974115],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9984302,0.00076692103,0.00020840626,0.00026036176,0.00022426402,0.000109845736],"domain_scores_gemma":[0.9951214,0.0013697644,0.0012307863,0.0009532228,0.0009319756,0.00039290902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004454588,0.0009596467,0.0019661281,0.00042173287,0.00058632286,0.0008601,0.0018963955,0.0015667866,0.022791004],"category_scores_gemma":[0.01037309,0.00037304772,0.0014194037,0.0009060533,0.00041000987,0.0006040426,0.0007619017,0.001484492,0.0064035784],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24948001,0.006045513,0.035143856,0.012895279,0.005826274,0.00027497715,0.00021366069,0.0011620205,0.0024212038,0.0016201643,0.6332835,0.051633555],"study_design_scores_gemma":[0.41255647,0.012714814,0.18504892,0.0028773707,0.0075551183,0.00062845036,0.0002583595,0.0034405596,0.0023258564,0.0024436293,0.36995712,0.00019338203],"about_ca_topic_score_codex":0.0063792164,"about_ca_topic_score_gemma":0.013587787,"teacher_disagreement_score":0.022791004,"about_ca_system_score_codex":0.0012365651,"about_ca_system_score_gemma":0.002679789,"threshold_uncertainty_score":0.07624346},"labels":[],"label_agreement":null},{"id":"W6964833193","doi":"10.25934/00000270","title":"A Multi-Center, Randomized, Phase 3 Study of Rituximab Versus Iodine I 131 Tositumomab Therapeutic Regimen For Patients With Relapsed Follicular Non-Hodgkins Lymphoma","year":2018,"lang":"en","type":"dataset","venue":"Vivli","topic":"Ecology and biodiversity studies","field":"Environmental Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Radioimmunotherapy; Regimen; Rituximab; Thyroid; Therapeutic index; Follicular phase; Iodine","score_opus":0.017391975781867023,"score_gpt":0.26180799210599287,"score_spread":0.24441601632412585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6964833193","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910703,0.00199626,0.0005009363,0.00043592285,0.00040807342,0.0039395983,0.00043505253,0.00010084365,0.0011130224],"genre_scores_gemma":[0.98833466,0.0012306386,0.0013785391,0.0013570891,0.00052492623,0.0048322612,0.00069617305,0.00002404412,0.0016217218],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99877316,0.0007322792,0.00006905458,0.00017563014,0.00008184635,0.00016802609],"domain_scores_gemma":[0.9984536,0.00042775978,0.00025715298,0.00013464893,0.000112644026,0.0006142511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029859503,0.0018668221,0.0036801153,0.000507821,0.00069757487,0.0013332627,0.0012775529,0.0020049717,0.0040525766],"category_scores_gemma":[0.0019428466,0.00093865837,0.002262501,0.00049047667,0.0012738281,0.0011174951,0.00040651593,0.0034285318,0.0009355507],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9739402,0.014150765,0.00055412174,0.00017986131,0.0005483098,0.000032758177,0.000051333704,0.00021471221,0.0022558025,0.000044733846,0.0003678869,0.007659577],"study_design_scores_gemma":[0.87265444,0.12466749,0.0016662413,0.000009282427,0.00021601615,0.000016372187,0.000014619205,0.00027221272,0.00017936502,0.000060482056,0.00023214657,0.000011348397],"about_ca_topic_score_codex":0.0012266418,"about_ca_topic_score_gemma":0.0029682002,"teacher_disagreement_score":0.0040525766,"about_ca_system_score_codex":0.0011046554,"about_ca_system_score_gemma":0.0017183936,"threshold_uncertainty_score":0.015791416},"labels":[],"label_agreement":null},{"id":"W7081132269","doi":"10.25934/pr00008913","title":"T1-DEXi-T Study: Does exercise training improve the time in range following acute bouts of exercise?","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"Geochemistry and Geologic Mapping","field":"Computer Science","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Exercise prescription; Wearable computer; Type 2 diabetes; Intervention (counseling); Cardiovascular health; Activities of daily living; Diabetes mellitus; Training (meteorology)","score_opus":0.010287753217640696,"score_gpt":0.2490431271474704,"score_spread":0.2387553739298297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7081132269","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6980781,0.066081844,0.018192228,0.035619467,0.011078412,0.018359292,0.08788949,0.0006638166,0.06403744],"genre_scores_gemma":[0.7819764,0.021829447,0.025760148,0.031369176,0.010123107,0.03743184,0.06809059,0.00062258577,0.022796808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975647,0.0011748349,0.0002598876,0.00047956328,0.00027974613,0.00024146208],"domain_scores_gemma":[0.9919686,0.0029344782,0.0012491441,0.001319573,0.0012707692,0.0012575194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007544691,0.0008672738,0.0017430834,0.0004902219,0.0009769124,0.0022560295,0.0014580659,0.002445581,0.009728325],"category_scores_gemma":[0.014088198,0.00039897303,0.0038429692,0.0010157079,0.0006284047,0.0019852994,0.0015429395,0.003140584,0.0037172823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25520015,0.018291524,0.24913089,0.019176027,0.017411774,0.00053204066,0.0016566435,0.0012167433,0.0059687207,0.005806264,0.103579655,0.3220296],"study_design_scores_gemma":[0.054677617,0.08057808,0.63921875,0.0069924737,0.023263304,0.0008337102,0.001568359,0.0018615847,0.0047971946,0.008808843,0.17681916,0.00058092916],"about_ca_topic_score_codex":0.002672495,"about_ca_topic_score_gemma":0.0046228804,"teacher_disagreement_score":0.009728325,"about_ca_system_score_codex":0.0006468093,"about_ca_system_score_gemma":0.0016374803,"threshold_uncertainty_score":0.03990066},"labels":[],"label_agreement":null},{"id":"W7084763686","doi":"10.25934/pr00008615","title":"Using artificial intelligence to predict and prevent physical activity induced hypoglycemia and hyperglycemia in type 1 diabetes","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"Forensic Anthropology and Bioarchaeology Studies","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Type 1 diabetes; Physical activity; Hypoglycemia; Diabetes mellitus; Continuous glucose monitoring; Artificial pancreas","score_opus":0.07355117522205301,"score_gpt":0.32670476401258475,"score_spread":0.25315358879053174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084763686","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0059717186,0.00034991224,0.0002502393,0.0004010861,0.00014239535,0.00006334793,0.9911851,0.00038517005,0.001250952],"genre_scores_gemma":[0.0056376974,0.00010895919,0.00085847755,0.0001095226,0.00001766058,0.00011199236,0.9923584,0.000016841757,0.00078044523],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993388,0.00014649204,0.00008324645,0.00018684317,0.00014771521,0.00009679623],"domain_scores_gemma":[0.99864465,0.00047237048,0.00013453604,0.00024653878,0.0003557306,0.00014616332],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011340021,0.0019729207,0.0010007594,0.0020026823,0.00057302427,0.001171597,0.0023578282,0.0020725203,0.011476163],"category_scores_gemma":[0.0045715417,0.00040561074,0.0016469205,0.0019266035,0.0003216953,0.000514479,0.001086923,0.0012825375,0.010474284],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005186087,0.0003131952,0.020393495,0.001102597,0.0002396268,0.00013608088,0.000044508008,0.003517705,0.000314676,0.00039434282,0.9579978,0.0150272995],"study_design_scores_gemma":[0.0024985434,0.0005469799,0.13711268,0.002063332,0.0008595958,0.0007069983,0.00081694004,0.037612367,0.0030249767,0.004358975,0.8101364,0.00026232598],"about_ca_topic_score_codex":0.06280421,"about_ca_topic_score_gemma":0.122717574,"teacher_disagreement_score":0.06280421,"about_ca_system_score_codex":0.0013533412,"about_ca_system_score_gemma":0.0015731197,"threshold_uncertainty_score":0.12487733},"labels":[],"label_agreement":null},{"id":"W7106120572","doi":"10.25934/pr00011790","title":"An analysis of outcome measures for the design of phase 2 futility trials in Alzheimer's Disease (AD)","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Disease; Clinical trial; Dementia; Outcome (game theory); Research design; Test (biology); Placebo; Randomized controlled trial","score_opus":0.26500974245698933,"score_gpt":0.4638805644370095,"score_spread":0.19887082198002015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7106120572","genre_codex":"methods","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06317436,0.007797712,0.74989516,0.004670046,0.007050022,0.1528192,0.004424615,0.0022022002,0.00796662],"genre_scores_gemma":[0.21756494,0.0010718607,0.416755,0.0025319671,0.0006135925,0.3563735,0.0017426828,0.0003644006,0.002982054],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.5083264,0.43815476,0.017737221,0.013150213,0.019048557,0.0035828315],"domain_scores_gemma":[0.504775,0.423923,0.028694252,0.026547419,0.013706976,0.0023533322],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.3413874,0.005044009,0.0106005175,0.005051785,0.0017387286,0.0036115423,0.003279147,0.0066345884,0.01644958],"category_scores_gemma":[0.44109282,0.001890826,0.018213697,0.0036782587,0.0038556657,0.004463248,0.0036230194,0.007984274,0.0020541765],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35501388,0.0062023825,0.016856505,0.018900232,0.0480895,0.0005522143,0.0018889914,0.03370331,0.004981334,0.08526418,0.024919042,0.40362838],"study_design_scores_gemma":[0.18115324,0.18335809,0.029063571,0.005900455,0.04398269,0.0006637161,0.0006370411,0.29737502,0.009846734,0.15954264,0.0873966,0.0010801931],"about_ca_topic_score_codex":0.0007013836,"about_ca_topic_score_gemma":0.0006464026,"teacher_disagreement_score":0.3413874,"about_ca_system_score_codex":0.0043893224,"about_ca_system_score_gemma":0.0061906106,"threshold_uncertainty_score":0.8121866},"labels":[],"label_agreement":null},{"id":"W7115935029","doi":"10.25934/pr00012083.0","title":"Available datapackage for study 'Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity'","year":2025,"lang":"en","type":"dataset","venue":"Vivli","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Semaglutide; Overweight; Weight loss; Body weight; Alternative medicine; Phone call","score_opus":0.01524119746711726,"score_gpt":0.27930603976770607,"score_spread":0.2640648423005888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115935029","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000103212806,0.0001143037,0.00006360011,0.00006591768,0.000018734849,0.000029887336,0.9991192,0.00011709146,0.0003680529],"genre_scores_gemma":[0.0011247952,0.00024452416,0.0005218946,0.0002804537,0.0000196507,0.00048545268,0.9960949,0.00014040676,0.001087937],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981134,0.000476984,0.0004355677,0.00039703868,0.00036486212,0.0002122417],"domain_scores_gemma":[0.9888469,0.0057715727,0.0018348714,0.0012888146,0.0016859948,0.0005717829],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032669974,0.001755994,0.0020948928,0.0021001326,0.0005948466,0.0018892211,0.002168189,0.0027124728,0.18680437],"category_scores_gemma":[0.020320864,0.00089041627,0.0026393938,0.0040522106,0.0002862124,0.0010832219,0.001616586,0.0016909788,0.06577089],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011951028,0.00008307929,0.002982313,0.006085346,0.00037586724,0.000032753953,0.000031472777,0.00035857395,0.00024724964,0.00047354584,0.9812231,0.006911576],"study_design_scores_gemma":[0.006919216,0.00028168838,0.021881877,0.0031256222,0.0008089236,0.00014416216,0.00006222112,0.0007348677,0.000610105,0.0017271263,0.963617,0.000087194785],"about_ca_topic_score_codex":0.017997637,"about_ca_topic_score_gemma":0.03054504,"teacher_disagreement_score":0.18680437,"about_ca_system_score_codex":0.001349627,"about_ca_system_score_gemma":0.0029989746,"threshold_uncertainty_score":0.6249229},"labels":[],"label_agreement":null}]}